Overview
This post details the strategic expansion of the SAKIGAKE system in 2026, a regulatory accelerator that redefines the market entry timeline for cutting-edge therapies and orphan drugs in Japan.
Introduction
Japan is reinforcing its global standing as a hub for medical excellence by significantly expanding the SAKIGAKE Designation system. This “fast-track” regulatory pathway is specifically engineered to prioritize innovative products that address high unmet medical needs and offer groundbreaking therapeutic benefits. In 2026, the PMDA has lowered the barriers for entry into this program, signalizing a clear invitation for global innovators to prioritize the Japanese market.
Concierge-Level Support and Accelerated Timelines
The 2026 expansion of SAKIGAKE broadens the eligibility criteria to include a wider array of gene therapies, regenerative medicines, and orphan drugs.
Securing this designation provides manufacturers with unparalleled regulatory advantages
Targeted 6-Month Review: While standard review timelines can be extensive, SAKIGAKE-designated products aim for a record-breaking 6-month review period, drastically accelerating market access.
Concierge-Style PMDA Support: Designated products receive a dedicated point of contact within the PMDA, ensuring seamless communication and “Priority Consultation” throughout the development and submission phases.
Pre-application Consultations: Access to specialized guidance helps manufacturers align their global data with Japanese standards early in the process, minimizing the risk of technical queries during the final review.
This system is designed not just to approve products faster, but to foster a collaborative environment where innovation meets safety in record time.
Conclusion
For companies developing breakthrough technologies, the SAKIGAKE system is more than a regulatory shortcut—it is a unique opportunity to establish a market-leading position in Japan. Success requires early engagement with the health authorities and a meticulously aligned global dossier. As the Japanese landscape becomes more receptive to rapid innovation, the SAKIGAKE pathway stands as the premier choice for companies ready to transform patient care in the region.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about.
- MHLW – Ministry of Health, Labour and Welfare: SAKIGAKE Strategy and Expansion Policy 2026.
- PMDA – Pharmaceuticals and Medical Devices Agency: Division of Priority Review Guidelines.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.
